TMO Thermo Fisher Scientific Inc | US8835561023
Financials
Trends
Details
| Breakdown | 31.12.2027 | 31.12.2026 | Change % |
|---|---|---|---|
| Total Revenue | 50.275.731.970 | 47.817.299.040 | 5.14% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| Operating Expense | -- | -- | -- |
| Selling General and Administrative | -- | -- | -- |
| Research & Development | -- | -- | -- |
| Operating Income | -- | -- | -- |
| Pretax Income | -- | -- | -- |
| Net Income Common Stockholders | -- | -- | -- |
| Basic EPS | 27,45 | 25,08 | 9.47% |
| Diluted EPS | -- | -- | -- |
| Analyst Count | 26 | 24 | 8.33% |
| EBIT | -- | -- | -- |
| EBITDA | -- | -- | -- |